Alamar Biosciences is a technology company.
Alamar Biosciences has raised $224.0M across 3 funding rounds.
Alamar Biosciences has raised $224.0M in total across 3 funding rounds.
Alamar Biosciences has raised $224.0M in total across 3 funding rounds.
Alamar Biosciences's investors include Forbion, Qiming Venture Partners, Illumina Ventures.
Alamar Biosciences is a Fremont, California-based life sciences company founded in 2020 that develops the NULISA platform for precision proteomics, enabling ultra-sensitive detection of protein biomarkers from minimal sample volumes like one microliter of plasma.[1][3][5] The platform serves academic researchers, biotech firms, and clinical developers focused on early disease detection, particularly for cancer, Alzheimer's, and inflammatory conditions, by solving key limitations in traditional immunoassays—such as poor sensitivity, high background noise, and limited multiplexing—through DNA-barcoded antibodies and sequential capture-release methods that achieve attomolar detection limits and 10,000-fold signal-to-noise improvements.[1][2][3] Growth momentum includes a $128 million oversubscribed Series C in 2024 (part of $204 million total funding), commercial launches of the ARGO HT automated system and NULISAseq Inflammation Panel 250, and recent products like the NULISAqpcr Custom Assay Development Kit in February 2025, with plans to expand commercialization, customer support, and IVD versions like ARGO DX for Alzheimer's diagnostics.[3][4]
Alamar Biosciences was founded in 2020 by Yuling Luo, PhD (Chairman & CEO), Steve Chen, PhD (COO), Yiyuan Yin, PhD (VP of Technology), with Xiao-Jun Ma, PhD as CTO and Tod White, JD as CFO/CBO.[1][5] The idea emerged from the founders' prior success at Advanced Cell Diagnostics (ACD), where they pioneered RNAscope, the gold standard in spatial genomics by maximizing signal-to-noise ratios; they applied these insights plus genomics advances to reinvent proteomics for liquid biopsy and multiplexed protein profiling.[5] Early traction built on this expertise, with rapid development of NULISA technology, securing ADDF funding for ARGO DX in Alzheimer's research, and launching commercial products like ARGO HT, which automates assays with under 30 minutes hands-on time.[2][3]
Alamar stands out in proteomics through:
Alamar rides the precision proteomics wave, aligning with booming demand for non-invasive liquid biopsies amid advances in genomics and multi-omics integration for early detection of diseases like cancer and neurodegeneration.[1][3][5] Timing is ideal as blood-based biomarkers for Alzheimer's transition from research to clinical use—decades of validation now meet NULISA's sensitivity gap-filling capabilities—while market forces like aging populations, personalized medicine pushes, and post-genomics proteomics hype (e.g., via NGS synergies) favor scalable platforms.[2][3] The company influences the ecosystem by accelerating biomarker discovery for pharma/biotech, enabling IVD tests, and standardizing high-throughput proteomics, potentially transforming diagnostics from reactive to proactive.[2][3]
Alamar is poised to dominate precision proteomics commercialization, leveraging Series C funds for team expansion, menu growth (e.g., more panels, IVDs like ARGO DX), and market penetration in research-to-clinic pipelines.[3] Trends like AI-driven multi-omics, single-cell proteomics standardization, and regulatory nods for blood tests will propel growth, with influence evolving from RUO innovator to diagnostics leader—unlocking the proteome's full potential for earliest disease detection, much like their RNAscope reshaped genomics.[2][3][5]
Alamar Biosciences has raised $224.0M across 3 funding rounds. Most recently, it raised $130.0M Series C in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $130.0M Series C | Forbion, Qiming Venture Partners | |
| Sep 1, 2021 | $80.0M Series B | Forbion, Illumina Ventures, Qiming Venture Partners | |
| May 1, 2020 | $14.0M Series A | Forbion, Qiming Venture Partners |